- Country: Sri Lanka
- Summary: Abciximab for Intravenous Infusion 10mg/5ml vial Abciximab for Intravenous Infusion 10mg in 5ml vial. Each 5ml vial to contain 10mg of Abciximab for intravenous infusion.
- LKT Ref No: 116243025
- Deadline: 24 Apr 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: DHS/P/WW/282/26
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Abciximab for Intravenous Infusion 10mg/5ml vial Abciximab for Intravenous Infusion 10mg in 5ml vial. Each 5ml vial to contain 10mg of Abciximab for intravenous infusion.
- Documents:
dhspww28226-67d3d0802ca965.91565918.pdf
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINAbciximab for Intravenous Infusion 10mg/5ml vial Abciximab for Intravenous Infusion 10mg in 5ml vial. Each 5ml vial to contain 10mg of Abciximab for intravenous infusion. - Srilanka Tender
The STATE PHARMACEUTICALS CORPORATION OF SRI LANKA, a Government sector organization in Sri Lanka, has announced a new tender for Abciximab for Intravenous Infusion 10mg/5ml vial Abciximab for Intravenous Infusion 10mg in 5ml vial. Each 5ml vial to contain 10mg of Abciximab for intravenous infusion.. This tender is published on SrilankaTender under LKT Ref No: 116243025 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-04-24.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
